Banco Santander S.A. Sells 18,373 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Banco Santander S.A. trimmed its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 13.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 120,000 shares of the company’s stock after selling 18,373 shares during the quarter. Banco Santander S.A. owned about 0.26% of Pacira BioSciences worth $1,806,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PCRX. GAMMA Investing LLC increased its stake in shares of Pacira BioSciences by 229.6% in the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after buying an additional 932 shares during the period. Park Place Capital Corp bought a new stake in Pacira BioSciences during the 2nd quarter worth about $46,000. Innealta Capital LLC bought a new stake in Pacira BioSciences during the 2nd quarter worth about $50,000. nVerses Capital LLC lifted its position in Pacira BioSciences by 800.0% during the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after purchasing an additional 1,600 shares during the period. Finally, Natixis bought a new position in shares of Pacira BioSciences in the 1st quarter valued at about $95,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Stock Up 1.0 %

PCRX opened at $17.55 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The firm’s fifty day simple moving average is $16.12 and its 200 day simple moving average is $20.40.

Analysts Set New Price Targets

PCRX has been the subject of a number of recent research reports. Barclays dropped their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Royal Bank of Canada raised their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. HC Wainwright dropped their price objective on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a report on Monday, August 12th. StockNews.com cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Finally, Truist Financial cut shares of Pacira BioSciences from a “buy” rating to a “sell” rating and decreased their price objective for the company from $30.00 to $8.00 in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.